HIV-associated conditions
HIV-associated neurocognitive disorder (HAND)
Represent a spectrum of progressive neurocognitive impairment:[6]Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007 Oct 30;69(18):1789-99.
http://www.ncbi.nlm.nih.gov/pubmed/17914061?tool=bestpractice.com
Asymptomatic neurocognitive impairment (ANI): acquired impairment in cognitive functioning involving at least 2 ability domains, documented by performance of at least 1 standard deviation (SD) below demographically corrected means for age-education-appropriate norms, but with no impairment in the ability to perform everyday activities.
Mild neurocognitive disorder: similar neurocognitive performance on neuropsychological tests as in ANI with mild interference in daily functioning at work or home, or in social functioning.
HIV-associated dementia: marked acquired impairment in cognitive functioning involving at least 2 ability domains, documented by performance of at least 2 SD below demographically corrected means and associated with a marked impairment in performing daily activities.
Effects of HIV therapy
Antiretroviral agents may induce cognitive and psychiatric problems directly as an adverse effect or indirectly through their effect on the immune system. The nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz is associated with the development of neuropsychiatric adverse effects, especially in the first weeks of treatment.[17]Blanch J, Martínez E, Rousaud A, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):336-43.
http://www.ncbi.nlm.nih.gov/pubmed/11468421?tool=bestpractice.com
[18]Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials. 2005 Jul-Aug;6(4):187-96.
http://www.ncbi.nlm.nih.gov/pubmed/16214735?tool=bestpractice.com
[19]Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review. 2010 Apr-Jun;12(2):67-75.
http://www.ncbi.nlm.nih.gov/pubmed/20571601?tool=bestpractice.com
[20]Cavalcante GI, Capistrano VL, Cavalcante FS, et al. Implications of efavirenz for neuropsychiatry: a review. Int J Neurosci. 2010 Dec;120(12):739-45.
http://www.ncbi.nlm.nih.gov/pubmed/20964556?tool=bestpractice.com
[21]Decloedt EH, Maartens G. Neuronal toxicity of efavirenz: a systematic review. Expert Opin Drug Saf. 2013 Nov;12(6):841-6.
http://www.ncbi.nlm.nih.gov/pubmed/23889591?tool=bestpractice.com
Rates of similar neuropsychiatric adverse effects are significantly lower with other NNRTI agents such as nevirapine, etravirine, and rilpivirine.[22]Cohen CJ, Andrade-Villanueva J, Clotet B, et al; THRIVE Study Group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011 Jul 16;378(9787):229-37.
http://www.ncbi.nlm.nih.gov/pubmed/21763935?tool=bestpractice.com
[23]Katlama C, Haubrich R, Lalezari J, et al; DUET-1, DUET-2 Study Groups. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009 Nov 13;23(17):2289-300.
http://www.ncbi.nlm.nih.gov/pubmed/19710593?tool=bestpractice.com
The integrase inhibitor raltegravir has been associated with infrequent neuropsychiatric adverse effects, and dolutegravir may be associated with insomnia and other central nervous system (CNS) effects.[24]Madeddu G, Menzaghi B, Ricci E, et al. Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study. AIDS. 2012 Nov 28;26(18):2412-5.
http://www.ncbi.nlm.nih.gov/pubmed/23032413?tool=bestpractice.com
[25]Harris M, Larsen G, Montaner JG. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008 Sep 12;22(14):1890-2.
http://www.ncbi.nlm.nih.gov/pubmed/18753871?tool=bestpractice.com
[26]Gray J, Young B. Acute onset insomnia associated with the initiation of raltegravir: a report of two cases and literature review. AIDS Patient Care STDs. 2009 Sep;23(9):689-90.
http://www.ncbi.nlm.nih.gov/pubmed/19663717?tool=bestpractice.com
[27]Walmsley SL, Antela A, Clumeck N, et al; SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013 Nov 7;369(19):1807-18.
http://www.nejm.org/doi/full/10.1056/NEJMoa1215541#t=article
http://www.ncbi.nlm.nih.gov/pubmed/24195548?tool=bestpractice.com
[28]Lepik KJ, Yip B, Ulloa AC, et al. Adverse drug reactions to integrase strand transfer inhibitors. AIDS. 2018 Apr 24;32(7):903-12.
http://www.ncbi.nlm.nih.gov/pubmed/29424784?tool=bestpractice.com
[29]van den Berk G, Oryszczyn J, Blok W, et al. Unexpectedly high rate of intolerance for dolutegravir in real life setting. Poster 948 presented at CROI 2016. February 2016 [internet publication].
http://www.croiconference.org/sessions/unexpectedly-high-rate-intolerance-dolutegravir-real-life-setting
Patients receiving antiretroviral therapy may also develop immune reconstitution inflammatory syndrome (IRIS), a paradoxical deterioration in clinical status associated with rapid improvement in CD4 counts and a decrease in viral loads within the first few months after ART initiation. IRIS develops as a consequence of the reaction of the restored immune system to infectious agents, most commonly Mycobacterium tuberculosis or M avium complex, although a variety of other causes (e.g., herpes simplex virus [HSV], varicella zoster virus [VZV], progressive multifocal leukoencephalopathy [PML], and Toxoplasmosis gondii) are also recognized triggers.[30]Torok ME, Kambugu A, Wright E. Immune reconstitution disease of the central nervous system. Curr Opin HIV AIDS. 2008 Jul;3(4):438-45.
http://www.ncbi.nlm.nih.gov/pubmed/19373003?tool=bestpractice.com
IRIS arising from underlying cryptococcal infection has also been described.[31]Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):130-4.
http://www.ncbi.nlm.nih.gov/pubmed/19365271?tool=bestpractice.com
Non-HIV-associated conditions
Systemic comorbidity
Concomitant nutritional deficiency (e.g., folate, vitamin B12, vitamin D) may cause cognitive impairment.[32]The Mind Exchange Working Group. Assessment, diagnosis and treatment of human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND): a consensus report of the Mind Exchange Program. Clin Infect Dis. 2013 Apr;56(7):1004-17.
http://www.ncbi.nlm.nih.gov/pubmed/23175555?tool=bestpractice.com
Patients with advanced HIV infection are at an increased risk of ischemic stroke.[33]Sico JJ, Chang CC, So-Armah K, et al; Veterans Aging Cohort Study. HIV status and the risk of ischemic stroke among men. Neurology. 2015 May 12;84(19):1933-40.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433456
http://www.ncbi.nlm.nih.gov/pubmed/25862803?tool=bestpractice.com
The underlying pathogenesis varies and includes cerebral emboli secondary to cardiac disease, as well as cerebral vasculitis as a consequence of syphilis or amphetamine/cocaine use.
HIV-infected patients with concomitant hepatitis C infection have higher rates of cognitive impairment.[32]The Mind Exchange Working Group. Assessment, diagnosis and treatment of human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND): a consensus report of the Mind Exchange Program. Clin Infect Dis. 2013 Apr;56(7):1004-17.
http://www.ncbi.nlm.nih.gov/pubmed/23175555?tool=bestpractice.com
[34]Hinkin CH, Castellon SA, Levine AJ, et al. Neurocognition in individuals co-infected with HIV and hepatitis C. J Addict Dis. 2008;27(2):11-7.
http://www.ncbi.nlm.nih.gov/pubmed/18681187?tool=bestpractice.com
Thyroid disease and hypogonadism are more common in patients with HIV, and can represent an underlying cause of altered mental status in HIV-infected people.[32]The Mind Exchange Working Group. Assessment, diagnosis and treatment of human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND): a consensus report of the Mind Exchange Program. Clin Infect Dis. 2013 Apr;56(7):1004-17.
http://www.ncbi.nlm.nih.gov/pubmed/23175555?tool=bestpractice.com
[35]Nelson M, Powles T, Zeitlin A, et al. Thyroid dysfunction and relationship to antiretroviral therapy in HIV-positive individuals in the HAART era. J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):113-4.
http://www.ncbi.nlm.nih.gov/pubmed/19092451?tool=bestpractice.com
[36]Lortholary O, Christeff N, Casassus P, et al. Hypothalamo-pituitary-adrenal function in human immunodeficiency virus-infected men. J Clin Endocrinol Metab. 1996 Feb;81(2):791-6.
http://www.ncbi.nlm.nih.gov/pubmed/8636305?tool=bestpractice.com
[37]Mayo J, Collazos J, Martínez E, et al. Adrenal function in the human immunodeficiency virus-infected patient. Arch Intern Med. 2002 May 27;162(10):1095-8.
http://archinte.jamanetwork.com/article.aspx?articleid=211446
http://www.ncbi.nlm.nih.gov/pubmed/12020177?tool=bestpractice.com
Psychiatric comorbidity
Psychiatric comorbidity is highly prevalent in HIV-infected people and can contribute to cognitive difficulties.[32]The Mind Exchange Working Group. Assessment, diagnosis and treatment of human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND): a consensus report of the Mind Exchange Program. Clin Infect Dis. 2013 Apr;56(7):1004-17.
http://www.ncbi.nlm.nih.gov/pubmed/23175555?tool=bestpractice.com
These include:
Depression
Alcohol and substance use disorders
Cognitive impact of many prescription drugs, in particular those with anticholinergic properties and psychotropic medications.[32]The Mind Exchange Working Group. Assessment, diagnosis and treatment of human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND): a consensus report of the Mind Exchange Program. Clin Infect Dis. 2013 Apr;56(7):1004-17.
http://www.ncbi.nlm.nih.gov/pubmed/23175555?tool=bestpractice.com